LIN-52 Inhibitors
Inhibitors of LIN-52 act primarily by interfering with the phosphorylation processes that are essential for its functional integration into the DREAM complex, which plays a pivotal role in cell cycle regulation and gene expression control. By targeting kinases responsible for activating LIN-52, these inhibitors can effectively reduce the protein's activity. This is achieved through the use of small molecules that inhibit a variety of kinases, including cyclin-dependent kinases (CDKs), which are crucial for the cell cycle progression. When CDKs are inhibited, LIN-52 cannot be properly phosphorylated, leading to its diminished role in the DREAM complex and thus affecting its ability to regulate gene expression during the cell cycle.
The chemical inhibitors designed to disrupt kinase activity exhibit a broad specificity, targeting multiple kinases that influence the phosphorylation status of LIN-52. The inhibition of CDK1, CDK2, CDK4, and CDK6 in particular, translates into a direct reduction in LIN-52's regulatory functions. Without the necessary phosphorylation by these kinases, LIN-52 is unable to carry out its role in the cell cycle checkpoints, resulting in a decrease in its overall activity within the DREAM complex.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor that disrupts various signaling pathways. LIN-52, being a part of the DREAM complex, is influenced by phosphorylation status; therefore, kinase inhibition can result in altered LIN-52 activity by preventing its proper phosphorylation and subsequent functional integration. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Cyclin-dependent kinase inhibitor that impedes cell cycle progression. LIN-52 is regulated by CDKs for its activity within the DREAM complex, thus inhibiting these kinases results in reduced LIN-52 function. | ||||||
Butyrolactone I | 87414-49-1 | sc-201533 sc-201533A | 200 µg 1 mg | $122.00 $514.00 | 1 | |
Selective inhibitor of CDKs, particularly CDK2. By targeting CDK2, the activation and function of LIN-52 within the DREAM complex is hindered, leading to decreased LIN-52 activity. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
A CDK inhibitor that can prevent the phosphorylation of proteins involved in cell cycle control. Inhibition of CDKs would lead to impaired LIN-52 phosphorylation, thereby diminishing its activity. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
A CDK inhibitor that can potentially alter the phosphorylation state of LIN-52, impacting its role within the DREAM complex and reducing its functional activity. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
An inhibitor of various kinases including CDKs. By inhibiting these kinases, the phosphorylation and thus the functional activity of LIN-52 is expected to be inhibited. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
CDK inhibitor with a preference for CDK1 and CDK2, which are involved in phosphorylation events that regulate LIN-52 activity. Inhibition of these kinases leads to decreased function of LIN-52. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
A CDK inhibitor affecting transcriptional regulators. By inhibiting CDKs, the phosphorylation status and activity of LIN-52 in the DREAM complex is compromised. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
This CDK4/6 inhibitor would disrupt the cell cycle-related functions of LIN-52 by preventing its phosphorylation through these CDKs. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
Targets multiple CDKs and could influence the phosphorylation-dependent regulation of LIN-52, thereby inhibiting its activity. | ||||||